{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:30Z","timestamp":1787120850157,"version":"build-2736575974"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor (ICI)-related cardiovascular toxicity is associated with high mortality, and prediction models may facilitate its prevention and management. However, the predictive performance, quality, risk of bias, and applicability of existing models remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review prediction models for ICI-related cardiovascular toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nine databases were searched for studies on prediction models for ICI-related cardiovascular toxicity from inception to July 12, 2026. Data were extracted in accordance with the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies. The included models were assessed using the Quality, Risk of Bias, and Applicability Assessment Tool for Prediction Models Using Regression or Artificial Intelligence Methods. This systematic review was registered on PROSPERO (CRD420261296378).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 34, 541 articles were identified, and 23 articles met the inclusion criteria. These 23 articles described 82 prognostic models (71 for predicting the occurrence risk of ICI-related cardiovascular toxicity and 11 for predicting the prognosis of this toxicity) and two diagnostic models. Modeling methods comprised logistic or Cox regression and machine learning algorithms. Common predictors included demographic characteristics, medical history, treatment-related characteristics, and laboratory and imaging parameters. The area under the receiver operating characteristic curves or C statistic ranged from 0.699 to 0.967 for apparent performance, 0.595 to 0.942 for internal performance, and 0.549 to 0.949 for external performance. Calibration and clinical utility were assessed in 20 and 15 models using calibration curves\/Hosmer\u2013Lemeshow test and decision curve\/clinical impact curve analysis, respectively, in apparent, internal, or external performance validation. Models were presented using techniques such as nomograms, scoring systems, and regression equations. All models were graded as low quality, high risk of bias, and only seven models were graded as high applicability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Existing prediction models have concerns regarding quality, risk of bias, and applicability, limiting their clinical practice. Currently, baseline and dynamic risk screening using relevant risk biomarkers is suggested to better manage ICI-related cardiovascular toxicity. Future research is warranted to validate and improve existing models or develop new prediction models with rigorous methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420261296378.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1903131","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:45:52Z","timestamp":1787118352000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prediction models for immune checkpoint inhibitor-related cardiovascular toxicity: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Miaomiao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Health and Management, Taishan Vocational College of Nursing","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defa","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ward 2, Gastroenterology Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Emergency Critical Care Medicine, Yantai Yuhuangding Hospital","place":["Yantai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Operating Room, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.012","article-title":"Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432813","article-title":"Efficacy and safety of immune checkpoint inhibitors as neoadjuvant therapy in perioperative patients with non-small cell lung cancer: a network meta-analysis and systematic review based on randomized controlled trials","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","article-title":"Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: The phase 3 EXTENTORCH randomized clinical trial","volume":"11","author":"Cheng","year":"2025","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.36128","article-title":"Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A meta-analysis","volume":"4","author":"J\u00e1come","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00486","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: Final analysis of the randomized, phase III KEYNOTE-585 study","volume":"43","author":"Shitara","year":"2025","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002056","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2025","journal-title":"Int J Surg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","first-page":"178","volume-title":"Handbook for the Management of Immunotherapy-Related Adverse Reactions","author":"Qin","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: International Cardio-Oncology Society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2940","article-title":"Cancer patients' experiences with immune checkpoint modulators: A qualitative study","volume":"9","author":"Ala-Leppilampi","year":"2020","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"E97","DOI":"10.1097\/ncc.0000000000000683","article-title":"Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: \"Real-world\" data","volume":"43","author":"Milne","year":"2020","journal-title":"Cancer Nurs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s12012-025-09990-6","article-title":"Predicting 30-day cardiotoxicity in patients receiving immune checkpoint inhibitors: An observational study utilizing XGBoost","volume":"25","author":"Li","year":"2025","journal-title":"Cardiovasc Toxicol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102908","article-title":"A literature review of treatment-specific clinical prediction models in patients with breast cancer","volume":"148","author":"Modi","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.8890","article-title":"Risk prediction models for incident primary cutaneous melanoma: a systematic review","volume":"150","author":"Vuong","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B22","unstructured":"Hu\n              YH\n            \n          \n          Guangzhou\n          Guangzhou Medical University\n          Influencing factors and diagnostic models of immune-related venous thromboembolism in patients with non-small cell lung cancer\n          \n          2024"},{"key":"B23","unstructured":"Li\n              QY\n            \n          \n          Beijing\n          Peking Union Medical College\n          Current status of immunotherapy-related cardiac toxicity and construction of predictive models in patients with non-small cell lung cancer\n          \n          2024"},{"key":"B24","unstructured":"Li\n              SS\n            \n          \n          Jinan\n          Shandong University\n          Study on predictive models of immune myocarditis in locally advanced or metastatic lung cancer with abnormal cardiac parameters\n          \n          2025"},{"key":"B25","unstructured":"Lu\n              R\n            \n          \n          Guangzhou\n          Guangzhou Medical University\n          Analysis of risk factors for major adverse cardiovascular events and establishment of predictive models in immune checkpoint inhibitor-related myocarditis\n          \n          2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.13764\/j.cnki.ncdm.2026.03.004","article-title":"Risk factor analysis and construction of predictive models for immune checkpoint inhibitor-related myocarditis","volume":"66","author":"Rao","year":"2026","journal-title":"J Nanchang Univ (Medical Sciences)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7507\/1671-6205.202511051","article-title":"Construction and validation of risk prediction model for venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors","volume":"25","author":"Su","year":"2026","journal-title":"Chin J Respir Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.12677\/acm.2025.1551486","article-title":"Analysis of risk factors for death due to cardiovascular toxicity and construction of predictive models in anti-PD-1\/PD-L1 therapy","volume":"15","author":"Yan","year":"2025","journal-title":"Adv Clin Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101435","article-title":"Multimodal fusion artificial intelligence model to predict risk for MACE and myocarditis in cancer patients receiving immune checkpoint inhibitor therapy","volume":"4","author":"Ayoub","year":"2025","journal-title":"JACC Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35514","DOI":"10.1038\/s41598-025-19460-2","article-title":"Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study","volume":"15","author":"Cheng","year":"2025","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2024.108360","article-title":"A two-stage ensemble learning based prediction and grading model for PD-1\/PD-L1 inhibitor-related cardiac adverse events: A multicenter retrospective study","volume":"255","author":"Cheng","year":"2024","journal-title":"Comput Methods Programs BioMed"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-24-556","article-title":"Development of peripheral biomarker-based prognostic nomograms for short-term and long-term survival in immune checkpoint inhibitor-associated myocarditis","volume":"15","author":"Guan","year":"2025","journal-title":"Cardiovasc Diagn Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002545","article-title":"Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach","volume":"9","author":"Heilbroner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1186\/s12885-025-13943-1","article-title":"Myocarditis prediction in locally advanced or metastatic lung cancer patients with cardiac parameters abnormalities undergoing immunotherapy: development and validation of a risk assessment model","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00432-024-05801-7","article-title":"Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysis","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70115","article-title":"Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China","volume":"13","author":"Liang","year":"2024","journal-title":"Cancer Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.21037\/tlcr-2025-aw-1252","article-title":"Development and external validation of a multivariable nomogram for predicting severe immune checkpoint inhibitor-associated myocarditis in advanced lung cancer","volume":"15","author":"Luan","year":"2026","journal-title":"Transl Lung Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/10760296251351020","article-title":"A new score for predicting immune checkpoint inhibitor-associated thrombosis in cancer patients","volume":"31","author":"Xia","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"B39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1248\/bpb.b25-00453","article-title":"Exploratory analysis for development predictive models of immune checkpoint inhibitor-induced myocarditis using a nationwide claims database","volume":"49","author":"Yamamoto","year":"2026","journal-title":"Biol Pharm Bull"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2026.1731591","article-title":"Predicting cardiovascular toxicity in anti-PD-1\/PD-L1 therapy: a risk factor analysis and model development","volume":"13","author":"Yan","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1186\/s12890-024-03323-z","article-title":"Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1762144","article-title":"Integrated risk stratification for ICI-associated myocarditis: a baseline hematological profile and a combined ECG and enzymatic signature at onset","volume":"17","author":"Zheng","year":"2026","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084062","article-title":"Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis","volume":"390","author":"Gomes","year":"2025","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0569","article-title":"Risk prediction models for cardiotoxicity of chemotherapy among patients with breast cancer: a systematic review","volume":"6","author":"Kabor\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad147","article-title":"Risk prediction models for antineoplastic-associated cardiotoxicity in treatment of breast cancer: a systematic review","volume":"80","author":"Rodriguez","year":"2023","journal-title":"Am J Health Syst Pharm"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2022.02.007","article-title":"Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis","volume":"33","author":"Tohidinezhad","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-073538","article-title":"Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA)","volume":"381","author":"Snell","year":"2023","journal-title":"BMJ"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.53190","article-title":"Mortality risk prediction models for people with kidney failure: a systematic review","volume":"8","author":"Jarrar","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1696142","article-title":"Risk prediction models for malnutrition in cancer patients: a systematic review and meta-analysis","volume":"12","author":"Yu","year":"2025","journal-title":"Front Nutr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2025.105094","article-title":"Risk prediction model for chemotherapy-induced nausea and vomiting in cancer patients: a systematic review","volume":"168","author":"Wang","year":"2025","journal-title":"Int J Nurs Stud"},{"key":"B53","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1186\/s12916-025-04367-6","article-title":"Prediction models for self-harm and suicide: a systematic review and critical appraisal","volume":"23","author":"Seyedsalehi","year":"2025","journal-title":"BMC Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101803","article-title":"Prediction models for depression risk among older adults: systematic review and critical appraisal","volume":"83","author":"Tan","year":"2023","journal-title":"Ageing Res Rev"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf095","article-title":"Prediction models for severe treatment-related toxicities in older adults with cancer: a systematic review","volume":"54","author":"Chan","year":"2025","journal-title":"Age Ageing"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Bmj"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcae038","article-title":"Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors","volume":"11","author":"Manderlier","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"B58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1903131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:45:55Z","timestamp":1787118355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1903131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2026.1903131"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1903131","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1903131"}}